Study IDs potential therapeutic target for glioblastoma | Nanospheres with gold could beat brain tumors, study finds | Excess weight tied to greater risk of 10 common cancers
Web Version
August 14, 2014
CONNECT WITH SNMMI LinkedInFacebookTwitterYoutube
SNMMI SmartBrief
News for nuclear medicine and molecular imaging professionals

Top Story
Study IDs potential therapeutic target for glioblastoma
Researchers have discovered that targeting the protein known as atypical protein kinase, or aPKC, inhibits several pathways associated with growth of glioblastomas, shrinking tumors, according to a mouse study published in the journal Science Signaling. This protein plays an important role in brain development, but in adults, it is associated with cancer. release (8/13)
Share: LinkedInTwitterFacebookGoogle+Email
Clinical News & Research
Nanospheres with gold could beat brain tumors, study finds
A new treatment that uses nanoscale gold particles coated with a chemotherapy drug effectively destroyed brain tumor cells when subjected to radiotherapy, with no cancer cells remaining 20 days later, according to a study in the journal Nanoscale. After the nanospheres were administered to a tumor sample, the cancer cells were given a dose of radiotherapy, which stimulated electrons in the gold, inflicting damage to the cancer cell DNA, while the chemotherapy also worked against the cancer. BBC (8/12)
Share: LinkedInTwitterFacebookGoogle+Email
Excess weight tied to greater risk of 10 common cancers
A U.K. study involving 5 million people found that obese or overweight individuals had a higher risk of developing 10 common cancers. The findings, published in The Lancet, showed the odds of developing leukemia and cancers of the uterus, gallbladder, kidney, cervix and thyroid rose for every additional five-point increase in BMI. Higher BMI also was associated with a greater risk of liver, colon, ovarian and breast cancer. The Independent (London) (tiered subscription model) (8/14), BBC (8/13)
Share: LinkedInTwitterFacebookGoogle+Email
Industry Report
Texas oncology firm obtains $11.8M in Series E financing
A Series E round of financing has pulled in $11.8 million for Castle Biosciences. The Texas-based firm will use the funding to make its cutaneous melanoma test more widely available clinically. The firm is scheduled early next month to release a biomarker-based test for use in esophageal cancer. Xconomy/Texas (8/13)
Share: LinkedInTwitterFacebookGoogle+Email
Intel, Michael J. Fox Foundation to use Big Data to study Parkinson's
A partnership between Intel and the Michael J. Fox Foundation for Parkinson's Research aims to assess patterns in data from smart watches and other wearables to better understand Parkinson's disease. The study, which involves 16 Parkinson's patients and nine controls, also includes contributions from the Tel Aviv Sourasky Medical Center in Israel and Mount Sinai Hospital in New York. VentureBeat (8/13)
Share: LinkedInTwitterFacebookGoogle+Email
News from the Field
Narrow provider networks take hold
Narrow provider networks have taken hold under the Affordable Care Act, and the trend is likely to continue, according to Dr. Robert Galvin, CEO at benefits advisory firm Equity Healthcare. Network performance is becoming a primary consideration in employer choice of network, Galvin says. Kaiser Health News (8/13)
Share: LinkedInTwitterFacebookGoogle+Email
Grants and Funding
NIH gives $7.1M grant to Dakotas health system for cancer studies
Sanford Health, with facilities in the Dakotas, has been awarded more than $7.1 million from the NIH's National Cancer Institute to further its cancer research. The funds will go toward clinical trials, as well as research into quality of life and care delivery for cancer patients, officials said. Ledger-Enquirer (Columbus, Ga.)/The Associated Press (8/12)
Share: LinkedInTwitterFacebookGoogle+Email
Advancing Health Care
Electronic records linked to better outcomes for patients
A study by HIMSS Analytics found the adoption of EMR systems is associated with improved outcomes for patients. Based on an analysis of 4,583 facility health records, hospitals that have EMR platforms with advanced capabilities were able to cut their mortality rates, especially for heart attack, small intestine surgery and respiratory failure. (free registration) (8/13)
Share: LinkedInTwitterFacebookGoogle+Email
The Chapter Roadshow is coming to Hagerstown, Md., and Burlington, Vt.
Join SNMMI-TS this August and September for informative half-day workshops on broadening the horizons of nuclear medicine technologists. Four VOICE credits are available, and breakfast will be provided for all participants. Learn more and register today for as low as $25.
Share: LinkedInTwitterFacebookGoogle+Email
Explore the new SNMMI Learning Center
SNMMI is pleased to present the new SNMMI Learning Center, designed to give you one-stop access to cutting-edge CE courses and transcript management in an easy-to-navigate format. Get started today.
Share: LinkedInTwitterFacebookGoogle+Email
Defeat is not the worst of failures. Not to have tried is the true failure."
-- George Woodberry,
American literary critic
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about SNMMI ->SNMMI | News | Meetings | Education | Publications | Membership
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Melissa Turner
Advertising:  Meryl Harold
  P: 202.407.7828

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information